Healthcare / Medical DevicesBrussels
$15.56
+0.08 (+0.52%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-32.1M · quality 37.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
53/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$453M
P/E
37.0x
↑EV/EBITDA
14.3x
↑ROE
10.0%
↑Gross Margin
32.2%
↓Debt/Equity
0.92
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+19.7%
FCF CAGR
—
FCF margin
-6.2%
FCF / Net income
-3.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $620.2M · net income $12.7M · FCF $-38.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $620.2M | $620.2M | $498.2M | $466.7M | $361.3M |
| Net Income | $12.7M | $12.7M | $9.3M | $-9.1M | $6.1M |
| EBITDA | $36.5M | $36.5M | $28.8M | $13.2M | $12.3M |
| EPS | 0.42 | 0.42 | 0.31 | -0.31 | 0.20 |
| Gross Margin | 32.2% | 32.2% | 33.7% | 28.8% | 35.1% |
| Operating Margin | 3.6% | 3.6% | 2.0% | 1.1% | 1.4% |
| Net Margin | 2.1% | 2.1% | 1.9% | -2.0% | 1.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.92 | 0.92 | 0.39 | 0.39 | 0.35 |
| Current Ratio | 0.99 | 0.99 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-38.4M | $-38.4M | $-18.0M | $-32.1M | $14.4M |
| Returns | |||||
| ROE | 10.0% | 10.0% | 8.3% | -8.6% | 5.2% |
| Valuation | |||||
| P/E | 37.05 | 37.05 | 42.77 | — | 79.32 |
| EV/EBITDA | 14.33 | 14.33 | 12.76 | 19.83 | 29.42 |
| P/B | 3.71 | 3.71 | 3.57 | 3.11 | 4.14 |
| Growth & Yield | |||||
| Revenue Growth | 24.5% | 24.5% | 6.7% | 29.2% | — |
| EPS Growth | 33.9% | 33.9% | 200.5% | -255.5% | — |
| Dividend Yield | 1.6% | 1.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
48.7%
EPS terminal req.
$1.38
Spread vs growth
-14.7%
5Y implied EPS CAGR
31.8%
EPS terminal req.
$1.67
Spread vs growth
2.2%
10Y implied EPS CAGR
20.4%
EPS terminal req.
$2.69
Spread vs growth
13.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+28.3%
Start / end P/E
39.1x → 37.0x
EPS bridge
0.31 → 0.42
Residual
-1.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.